Adding Rituxan Boosts Survival 50% in DLCL

The British Columbia (Canada) Cancer Agency is reporting today that adding rituxan to standard chemotherapy for diffuse large b-cell lymphoma (DLCL) significantly improved survival rates.

Before the introduction of rituxan, half of patients with DLCL were alive two years after diagnosis; since doctors began adding the drug, more than 75 per cent of patients are alive, said Dr. Sehn, a medical oncologist at the B.C. Cancer Agency. "So in essence, we've been able to reduce the death from this kind of cancer by more than half."
Articles

LymphomaInfo Social